AC Immune SA (ACIU)
| Market Cap | 375.61M |
| Revenue (ttm) | 17.54M |
| Net Income (ttm) | -70.36M |
| Shares Out | 72.65M |
| EPS (ttm) | -1.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 467,256 |
| Open | 5.79 |
| Previous Close | 5.35 |
| Day's Range | 5.05 - 5.41 |
| 52-Week Range | 4.81 - 12.61 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 15.18 (+193.5%) |
| Earnings Date | Nov 12, 2021 |
About ACIU
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Ph...
Analyst Forecast
According to 3 analysts, the average rating for AC Immune stock is "Strong Buy." The 12-month stock price forecast is 15.18, which is an increase of 193.55% from the latest price.
News
AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer's Vaccine Generates a Po...
Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment
AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to...
Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the rat...
AC Immune (ACIU) Reports Q3 Loss, Misses Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of 17.24% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimer's disease
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune Extends Research Collaboration with University of Pennsylvania Focusing on the Pathogenic Protein TDP-43, a...
LAUSANNE, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases,...
New Data on AC Immune's Abeta and pTau Clinical Programs in Alzheimer's Disease To Be Presented at CTAD 2021
LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today anno...
AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof.
Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization
AC Immune to Present at the Jefferies London Healthcare Conference
LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today annou...
Alzheimer's Drug for Roche Partner AC Immune Shows Promise
The ardor for shares of AC Immune SA ( ACIU , Financial) has cooled considerably since the company's Aug. 31 announcement of somewhat promising study results for its Alzheimer's drug. The Swiss biotech'...
AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year
LAUSANNE, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases...
AC Immune to Participate in Upcoming Virtual Investor Conferences in September
LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today anno...
AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study
AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16%
What Leerink, Wainwright Have To Say For This Alzheimer's Focused Firm
Earlier today, AC Immune SA (NASDAQ:ACIU) announced semorinemab met one of its co-primary endpoints in a mid-stage Alzheimer's disease trial. SVB Leerink notes that semorinemab data is "good news.
ACIU Stock: The Big Alzheimer's News That Has AC Immune Skyrocketing Today
AC Immune (ACIU) stock is rising higher on Tuesday after revealing positive results from a recent Alzheimer's disease study. The post ACIU Stock: The Big Alzheimer's News That Has AC Immune Skyrocketing...
Here's Why AC Immune Stock Is Surging Today
MIxed results for the company's Alzheimer's disease candidate are good enough for the market today.
See Why AC Immune Stock Is Trading Higher After Data From Alzheimer's Candidate
AC Immune SA (NASDAQ: ACIU) and its collaborating partner Genentech, part of Roche Holdings AG (OTC: RHHBY), have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alz...
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer's Disease
Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of -31.82% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Announced strategic acquisition of industry-leading Parkinson's disease vaccine and equity investment led by key investors in Covid-19 vaccine innovator BioNTech SE
AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkin...
ACI-24 generated an encouraging immune response that correlated with a signal of target engagement in patients with Down syndrome (DS)
Earnings Preview: AC Immune (ACIU) Q2 Earnings Expected to Decline
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune Secures Funding From BioNTech Investors, Buys Parkinson's Vaccine Candidate
AC Immune SA (NASDAQ: ACIU) has gained a multi-million investment from the principal backers of BioNTech SE (NASDAQ: BNTX) while acquiring a possible Parkinson's disease vaccine. It announced a $25 mill...
AC Immune acquires AFFiRiS' Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegener...
VIENNA, Austria, July 27, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying Specific Active Immunotherapies ...
AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Invest...
All-stock transaction maintains AC Immune's strong cash position